The treatment of older patients with acute myeloid leukaemia, who are not considered suitable for conventional intensive therapy, is unsatisfactory. Low-dose Ara-C(LDAC) has been established as superior to best supportive care, but only benefits the few patients who enter complete remission. Alternative or additional treatments are required to improve the situation. This randomised trial compared the addition of the immunoconjugate, gemtuzumab ozogamicin (GO), at a dose of 5 mg on day 1 of each course of LDAC, with the intention of improving the remission rate and consequently survival. Between June 2004 and June 2010, 495 patients entered the randomisation. The addition of GO significantly improved the remission rate (30% vs 17%; odds ratio(OR) 0.48 (0.32-0.73); P ¼ 0.006), but not the 12 month overall survival (25% vs 27%). The reason for the induction benefit failing to improve OS was two-fold: survival of patients in the LDAC arm who did not enter remission and survival after relapse were both superior in the LDAC arm. Although the addition of GO to LDAC doubled the remission rate it did not improve overall survival. Maintaining remission in older patients remains elusive.
INTRODUCTION
A substantial proportion of older patients with acute myeloid leukaemia (AML) are not considered fit for, or likely to benefit from, intensive chemotherapy. The usual decision is to offer such patients a less intensive or even completely palliative approach with supportive care. With changing population demographics more patients in this category will emerge in future years. The definition of this patient group is imprecise, but is generally based on age as a surrogate for performance score and co-morbidity. 1 More detailed 'scores' have been developed that lead to more objectivity, because age itself may have little relationship to the ability to withstand chemotherapy. [2] [3] [4] [5] While the decision usually results from a patient-physician discussion, some patients have a preference to choose a non-intensive approach if it offers less hospitalisation. The recent population-based study carried out in Sweden indicated that older patients treated in centres that offered an intensive approach had a better survival than those treated in centres offering best supportive care. 6 Because the reasons for the treatment choice are not clear or not defined, the important academic dilemma of who should receive intensive or non-intensive treatment can only definitely be clarified by randomisation based on the uncertainty principle. Such studies are few, but one trial compared the application of intensive chemotherapy against a watch-and-wait approach. 7 There was no difference in overall survival and the study was too small to define subgroups who would benefit from one or other approach. The UK LRF AML14 trial 8 attempted to test this by randomising patients to an intensive approach involving daunorubicin/ cytarabine-based intensive treatment or a non-intensive approach, which compared a schedule of 10-day twice-daily courses of low-dose cytarabine (LDAC) vs best supportive care. Only 8 out of almost 1600 patients were randomised. The nonintensive part of the trial was prematurely stopped because LDAC emerged as statistically superior to best supportive care with no extra toxicity, supportive care requirements or hospitalisation. 9 This provided a standard of care for these patients, which has been challenged by alternatives but not superseded by a survival benefit. 10, 11 It however remains an unsatisfactory treatment. In AML14, it appeared that any survival benefit was limited to patients who entered remission. Since this trial, a number of attempts have been made to develop treatment for this unmet need, none of which has so far proved to be clearly superior to LDAC given in this schedule. In order to assess new treatments rapidly we developed a trial design, which we designated 'Pick a Winner', the operational characteristics and initial experience of which we have provided in detail elsewhere. 12 Briefly the purpose is to randomise a number of new treatments contemporaneously against LDAC. The aim is to find a treatment that could double the complete remission (CR) rate on the basis that to double the survival at 2 years from around 11-22% would require a doubling of CR rate to 430% compared with 15-18% achieved with LDAC. At two interim points, after 50 and 100 patients have been randomised to the novel arm, the DMEC is asked to indicate if this is likely. If it is not, the treatment is discarded. If the promise is likely to be fulfilled, then the randomisation continues with overall survival as the primary endpoint. The immunoconjugate gemtuzumab ozogamicin (Mylotarg) (GO) gained approval in the US and Japan for the treatment of relapsed AML in patients over 60 years for whom intensive therapy was not thought to be suitable. As monotherapy for untreated older patients it had modest efficacy in unrandomised studies. 13, 14 When combined with chemotherapy at the licensed dose of 9 mg/m 2 it caused liver toxicity. 15 At lower doses of 3 or 6 mg/m 2 in combination with standard chemotherapy tolerability has been acceptable although there was an increased risk of induction deaths in the GO arm in the post approval pivotal trial (SWOG 0106), 16 which contributed to its voluntary removal from the US market in June 2010. This detrimental effect has not been seen in a subsequent 3000 randomised patients in three other combination trials with doses of up to 3 mg/m 2 . [17] [18] [19] We here report the results of one of the interventions in our UK NCRI AML 14 and16 trials, which was based on the 'pick-a-winner' design in which LDAC was compared with LDAC þ GO.
METHODS Treatment
This was an open label randomised (1:1) comparison between LDAC 20 mg twice a day by subcutaneous injection for 10 days at B6 week intervals and the same LDAC treatment with GO give as a flat dose of 5 mg on day 1 of each course for up to four courses. Patients' blasts were not required to be CD33 positive. Thereafter patients who were considered to be benefiting from LDAC could have additional courses without GO.
Inclusion and exclusion criteria
The AML14 and 16 trials both offered an intensive treatment option. In AML16, the reason why a patient was not considered suitable for intensive treatment and details of co-morbidity (using the Sorror index 3 components) were collected at entry. The distribution of patients by the multi-parameter risk score (Wheatley score 2 ) over and under 75 years was 4% vs 2% favourable: 42% vs 45% intermediate; and 55% vs 52% poor risk. This validated score predicted a 12 month survival of 36%, 42% and 14% for LDAC in the three risk groups. Of the co-morbidities listed, most frequent were those described as cardiac, in 22% of patients. Diagnosis and response definitions were designated by the local investigator. Cytogenetic and immunophenotypic characterisation was carried out in regional reference laboratories who participate in national quality assurance schemes. Patients were required to give written consent and the trial was approved by the Wales Research Ethics Committee in compliance with the Declaration of Helsinki.
Toxicity
Adverse events and toxicity was recorded as defined by the NCI CTC version 3.
Statistical considerations
Definitions of endpoints. The protocol defined CR as a normocellular bone marrow aspirate containing o5% leukaemic blasts and showing evidence of normal maturation of other marrow elements. Persistence of myelodysplastic features did not preclude the diagnosis of CR. Although not in the original protocol, in this report, to achieve CR patients required neutrophil recovery to 1.0 Â 10 9 /l and platelets to 100 Â 10 9 /l, without evidence of extra-medullary disease. Patients who achieved CR according to the protocol, but without recovery, are denoted here as CRi. Assessment of remission status was undertaken after each treatment course until status was confirmed.
Following the international guidelines, 20 overall survival (OS) is defined as the time from randomisation to death. For remitters, survival from CR is defined as the time from CR/CRi (first report) until death. Relapse-free survival is the time from remission to either death or relapse, whichever occurs first. Surviving patients are censored at date last seen, and follow-up is complete to 1 January 2012. Median follow-up for survival is 40 months (range 1-55). Survival percentages are quoted at 1 year.
Statistical methods. All analyses are by intention to treat. Categorical endpoints (for example, CR rates) were compared using Mantel-Haenszel tests, giving Peto odds ratios and confidence intervals. Continuous variables were analysed by parametric (t-test) or non-parametric (Wilcoxon rank sum) tests as appropriate. Time-to-event outcomes were analysed using the log-rank test, with Kaplan-Meier survival curves. Odds/hazard ratios (OR/HR) o1 indicate benefit for GO over LDAC alone.
In addition to overall analyses, subgroup analyses were performed by the randomisation stratification parameters and other important variables, Gemtuzumab ozogamicin in acute myeloblastic leukaemia AK Burnett et al with suitable tests for interaction. Because of the well-known dangers of subgroup analysis, these were interpreted cautiously. Under the rules of the 'pick-a-winner' design, the DMEC would examine data once CR information was complete for 100 patients. This occurred at the closure of AML14 once 108 patients had been randomised. The requirement to continue was for at least a 2.5% improvement in overall response rate (ORR) (CR þ CRi) in favour of LDAC þ GO. In this case remission rates were 33% vs 8%, and the decision was taken to continue with recruitment as part of AML16. After data were available on 200 patients, a 7.5% improvement in ORR was required to extend the trial to at least 400 patients with a primary outcome of overall survival. In this case, the respective ORRs were 31% vs 13%. The characteristics of the patients are shown in Table 1 . The median age was 75 years (range 54-90), 61% were male, 325 had de novo disease, 106 had secondary disease either to a prior haematological disorder (n ¼ 73) or to previous chemotherapy for another malignancy (n ¼ 19), with this information unknown on 14 patients. Sixty-five patients had high risk myelodysplastic syndrome. With respect to our previously published ' Gemtuzumab ozogamicin in acute myeloblastic leukaemia AK Burnett et al 16 trials during the period of the non-intensive GO randomisation ( Table 1 ). The treatment arms were balanced for the patient characteristics. The reasons for choosing a non-intensive approach were: age 71%, unfitness 61% and other reasons 12% ( Table 2 ). The number of courses delivered for LDAC was 3.0 (mean), 2.0 (median), range 0-8, and for LDAC þ GO was 2.5 (mean), 2.0 (median), range 0-8.
RESULTS

Patients
Remission induction
The addition of GO significantly improved the remission rate from 11 to 21% (OR 0.46 (0.29-0.75) P ¼ 0.002). The rate of CRi (marrow CR with incomplete count recovery) was similar (6% vs 9%), leading to an increase in overall response rate from 17 to 30% (OR 0.48 (0.32-0.73), P ¼ 0.006). This was achieved by a reduction in resistant disease from 67 to 52% with no difference in 30-day mortality (16% vs 18%). (Table 2 ). The 56-day mortality was not significantly increased in the GO arm (LDAC 27% vs LDAC þ GO 29%) ( Table 3 ).
Toxicity and supportive care
The reported toxicities after the first 2 courses and the supportive care requirements are shown in Table 4 . There was a significant difference in nausea and vomiting in course 1, and a modest but significant increase in liver toxicity after course 2 in the GO arm. There were no reported cases of veno-occlusive liver disease.
Gastrointestinal toxicity was greater in the GO arm. More blood products, days on antibiotics and hospitalisation were required in the GO arm in courses 1 and 2.
Relapse-free survival and survival following remission The relapse-free survival at 1 year for the 40 patients in the control arm was 40%, which was not significantly different from that for the 74 patients in the GO arm (31%; HR 1.11 (0.73-1.67), P ¼ 0.6; Figure 1a) . Similarly, survival from remission was not significantly different (LDAC 62% vs LDAC þ GO 55%, HR 1.31 (0.86-2.01), P ¼ 0.2; Figure 1b) . However, among patients who relapsed, there was some evidence that survival following relapse was better in the LDAC arm (37%) than the LDAC þ GO arm (11%; HR 1.49 (0.93-2.48), P ¼ 0.09; Figure 1c ).
Overall survival Despite the significant increase in remission rate and comparable relapse-free survival, there was no difference in overall survival at 12 months (LDAC 25% vs LDAC þ GO 27%, HR 0.99 (0.83-1.16), P ¼ 0.9; Figure 1d ). This can partly be accounted for by the apparently worse survival in LDAC þ GO treated patients who relapsed compared with LDAC, but also the fact that among patients who did not achieve remission, survival was significantly better with LDAC (LDAC 15% vs LDAC þ GO 9%; HR 1.27 (1.03-1.56), P ¼ 0.03; Figure 1e ). In an exploratory analysis of potential prognostic subsets the benefit of GO on remission rates (CR or CRi) was seen in most subgroups (Supplementary Figure 1) , with no significant evidence of interaction, although there was a suggestion that the effect was greater in patients with higher white blood cell counts at randomisation, and the effect appeared larger in the 277 patients who were in the Wheatley poor-risk group. There was no subgroup in which there was any suggestion of an overall survival benefit including CD33 status (Supplementary Figure 2) , although the benefit of GO was greater in patients with higher WBC. As the dose given was a flat 5 mg dose, there was variation in the dose when expressed per square metre such that 23% of patients would have received o2.5 mg/m 2 , 53% between 2.5-3.0 mg/m 2 and 24% more than 3.0 mg/m 2 . However, stratified analysis showed no difference in treatment effect by different doses per square metre ( Supplementary Figures 1 and 2) .
DISCUSSION
The population of older patients with AML is likely to increase as a result of demographic changes in the population. These so called 'unfit' patients have until recently be neglected by collaborative group studies. While LDAC has been established as superior and no more toxic than supportive care, it is far from a satisfactory treatment. Several agents have been able to achieve higher remission rates in unrandomised studies in this age group, 10, 11, 21 but none has been demonstrated in randomised trials as superior to the LDAC schedule used here.
The point of the pick-a-winner trial design is to rapidly identify treatments that might improve survival in this patient group, while eliminating treatments that are unlikely to do so. Our previous trial, which identified LDAC as an interim standard of care, suggested that survival benefit was only seen in patients who entered CR. CR therefore represented an early surrogate marker for treatments that could be expected to deliver an improvement in survival. This would enable a decision to be made to continue or reject a particular treatment at a relatively early stage (that is, 100 randomised or after 87 events, usually deaths). In this study the 'continue' decision was made after 108 patients had been randomised and based upon the difference in remission rates a significant improvement in survival was projected. In the final analysis of the 496 recruited patients the remission rate was indeed doubled. This could reasonably have been expected to deliver a superior survival, because in our original trial of LDAC the median survival of patients entering remission was 19 months, compared with 2 months for those who did not. In the current trial an improved survival was not delivered in spite of doubling the rate of remission. It might be speculated that GO was able to deliver some additional higher-risk patients to remission who had an inherently higher relapse risk, so that, while they might enter remission, they would relapse more quickly and this would be apparent in the relapse-free survival. However this is not what was seen. The rate of relapse was not different. The failure to translate into a superior survival was accounted for by a better survival after relapse in the LDAC arm and an inferior survival in patients who did not achieve remission in the GO arm.
While there may be benefits such as quality of life in being in remission, these were not measured in this study. It appears that while the achievement of CR may be, in the main, a necessary requirement for improved survival this study suggests that it is an inadequate surrogate for it. This may be a particular feature of AML in older patients. It is further endorsed by studies of demethylating agents, which for some patients, improve survival without achieving CR. 22, 23 The pick-a-winner design can account for mechanistic differences of different drugs by incorporating a decision, particularly at the second stage, based not on remission rate but on survival.
There are now reports of four randomised trials where GO was added to induction treatment, three of which demonstrate that, while not improving the remission rate, it can significantly reduce the relapse rate and thereby improve overall survival, [16] [17] [18] [19] which could make a case for its use despite its withdrawal from the US market. At least four randomised trials have evaluated GO in consolidation or maintenance without showing any benefit, although not all of these studies were adequately powered. 16, 17, 24, 25 In the patient population under study here novel treatments may be successful in delivering remissions, but not overall survival, so the challenge of maintaining remission remains.
CONFLICT OF INTEREST
